Cell therapy trial aims to halt vision loss in dry AMD
NCT ID NCT05626114
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a cell therapy called OpRegen for people with geographic atrophy, an advanced form of dry age-related macular degeneration that causes blind spots. About 60 participants will receive a one-time injection of retinal cells under the retina during eye surgery. The main goals are to see if the delivery works safely and if it can improve or preserve vision.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
OpRegen (a retinal cell therapy)
What this could lead to
If successful, this could point toward a treatment that slows or stops vision loss from geographic atrophy.
What could go wrong
This is an early Phase IIa study with only 60 people, so results may not apply to everyone. The surgical delivery itself carries risks like infection or retinal damage.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GEOGRAPHIC ATROPHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Austin Clinical Research, LLC
RECRUITINGAustin, Texas, 78750-2298, United States
-
Cincinnati Eye Institute
RECRUITINGBlue Ash, Ohio, 45242-5537, United States
-
Duke Eye Center
RECRUITINGDurham, North Carolina, 27705-4699, United States
-
Hadassah MC
RECRUITINGJerusalem, 9112001, Israel
-
Mid Atlantic Retina
RECRUITINGPhiladelphia, Pennsylvania, 19107-5109, United States
-
Piedmont Eye Center
RECRUITINGLynchburg, Virginia, 24502-4271, United States
-
Retina Consultants of Texas
RECRUITINGBellaire, Texas, 77401, United States
-
Retina Vitreous Associates of Florida
RECRUITINGSt. Petersburg, Florida, 33711-1141, United States
-
Retina-Vitreous Associates Medical Group
RECRUITINGBeverly Hills, California, 90211, United States
-
Retinal Consultants Medical Group
RECRUITINGSacramento, California, 95825, United States
-
Sierra Eye Associates
RECRUITINGReno, Nevada, 89502-1605, United States
-
Spokane Eye Clinical Research;Spokane Eye Surgery Center
RECRUITINGSpokane, Washington, 99204, United States
-
Tel Aviv Sourasky MC
RECRUITINGTel Aviv, 6423906, Israel
-
Tennessee Retina PC
RECRUITINGNashville, Tennessee, 37203-1513, United States
-
The Retina Care Center
RECRUITINGBaltimore, Maryland, 21209-2219, United States
-
The Retina Institute
RECRUITINGSt Louis, Missouri, 63128-1729, United States
-
West Coast Retina
RECRUITINGSan Francisco, California, 94109-5520, United States